Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.
CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
Cue is a healthcare technology company that enables people to manage their health through actionable and connected health data.
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.
Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Sermonix Pharmaceuticals is an Ohio LLC specialty pharmaceutical.
Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.
Zentera Therapeutics is a biopharmaceutical company.
Motus GI touted clinical data evaluating its Pure-Vu cleaning system.
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
Singular Genomics is a biotech company focused on delivering genomic technologies for the advancement of science and medicine.
Renovia was a developer of prescription digital therapeutics for pelvic floor disorders. Renovia ceased operations in late 2022.
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.
Rain Oncology is a operator of a clinical stage biotechnology company.
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 27 different industry categories.
Among tracked funding rounds, Blueprint Medicines received $1.3B in a Post Ipo Equity round. Perceptive Advisors's total known invested capital is $26.6B.
Perceptive Advisors's average investment size is $135.1M across its portfolio of 224 companies.
Recent Perceptive Advisors portfolio additions include RayzeBio, Point Biopharma, CinCor Pharma, Achilles Therapeutics, Blueprint Medicines. These companies were founded in 2020 or later.